- Home
- ONEG vs AKTX Comparison
ONEG vs AKTX Comparison
Compare ONEG & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONEG
- AKTX
- Stock Information
- Founded
- ONEG 2021
- AKTX N/A
- Country
- ONEG Hong Kong
- AKTX United States
- Employees
- ONEG N/A
- AKTX N/A
- Industry
- ONEG Homebuilding
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- ONEG Consumer Discretionary
- AKTX Health Care
- Exchange
- ONEG Nasdaq
- AKTX Nasdaq
- Market Cap
- ONEG 43.3M
- AKTX 35.7M
- IPO Year
- ONEG 2024
- AKTX N/A
- Fundamental
- Price
- ONEG $5.81
- AKTX $0.99
- Analyst Decision
- ONEG
- AKTX Strong Buy
- Analyst Count
- ONEG 0
- AKTX 1
- Target Price
- ONEG N/A
- AKTX $5.00
- AVG Volume (30 Days)
- ONEG 25.8K
- AKTX 28.3K
- Earning Date
- ONEG 01-01-0001
- AKTX 08-18-2025
- Dividend Yield
- ONEG N/A
- AKTX N/A
- EPS Growth
- ONEG N/A
- AKTX N/A
- EPS
- ONEG 0.12
- AKTX N/A
- Revenue
- ONEG $60,903,000.00
- AKTX N/A
- Revenue This Year
- ONEG N/A
- AKTX N/A
- Revenue Next Year
- ONEG N/A
- AKTX N/A
- P/E Ratio
- ONEG $46.63
- AKTX N/A
- Revenue Growth
- ONEG 16.46
- AKTX N/A
- 52 Week Low
- ONEG $1.48
- AKTX $0.85
- 52 Week High
- ONEG $10.80
- AKTX $4.22
- Technical
- Relative Strength Index (RSI)
- ONEG N/A
- AKTX 31.58
- Support Level
- ONEG N/A
- AKTX $0.97
- Resistance Level
- ONEG N/A
- AKTX $1.06
- Average True Range (ATR)
- ONEG 0.00
- AKTX 0.04
- MACD
- ONEG 0.00
- AKTX -0.01
- Stochastic Oscillator
- ONEG 0.00
- AKTX 2.22
About ONEG OneConstruction Group Limited Ordinary Shares
OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. It is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction project include performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.